tradingkey.logo

Acrivon Therapeutics Announces Positive Acr-368 Phase 2B Endometrial Cancer Clinical Data

ReutersJan 8, 2026 12:54 PM

- Acrivon Therapeutics Inc ACRV.O:

  • ACRIVON THERAPEUTICS ANNOUNCES POSITIVE ACR-368 PHASE 2B ENDOMETRIAL CANCER CLINICAL DATA WITH EU EXPANSION TO ACCELERATE ENROLLMENT, INITIAL ACR-2316 CLINICAL DATA, AND ACR-6840, ITS NEXT AP3-ENABLED DEVELOPMENT CANDIDATE, TARGETING CDK11

  • ACRIVON THERAPEUTICS INC - ACR-2316 PHASE 1 SHOWS FAVORABLE TOLERABILITY

  • ACRIVON THERAPEUTICS INC: ACR-6840 IND SUBMISSION PLANNED FOR Q4 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI